skip to main content

Hormone-free interval-associated headache — DFSRH MCQ

Instant feedback + full explanation. One question, done properly.

EasyVaginal RingHormone-free interval-associated headacheDFSRH

A 32-year-old woman has used an ethinylestradiol/etonogestrel vaginal ring for 12 months. During each 7-day ring-free interval, she develops a bilateral pressure-type headache beginning 2 days after ring removal and resolving within 24 hours of inserting the next ring. She has no nausea, photophobia, aura or focal neurological symptoms, and does not experience headache while the ring is in situ. Her blood pressure is normal, she does not smoke, and review identifies no contraindication to combined hormonal contraception. She wishes to continue the vaginal ring and would prefer to avoid both the headaches and scheduled withdrawal bleeding. Which vaginal-ring regimen is most appropriate?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: AReplace each ring after 21 days without a ring-free interval

Explanation lettering: C = shown as A · E = shown as B · B = shown as C · A = shown as E

The temporal relationship identifies a hormone-free interval-associated headache rather than headache occurring during hormone exposure. She has no features of migraine with aura or another new contraindication to combined hormonal contraception. As she wishes to avoid both the headaches and scheduled withdrawal bleeding, continuous ring use—replacing each ring after 21 days with no hormone-free interval—best meets her objectives. This is an off-label regimen supported by FSRH; she should be counselled that unscheduled bleeding may occur. A retains the 7-day hormone-free interval that precipitates her symptoms. B is a supported tailored regimen and may reduce withdrawal symptoms, but it retains a monthly hormone-free interval and scheduled bleeding. D reduces the frequency of withdrawal episodes but still exposes her to a 7-day interval every 9 weeks. E resembles flexible extended use, but FSRH specifies a 4-day hormone-free interval after breakthrough bleeding, not 7 days; moreover, it is less aligned with her preference to avoid planned interruptions. A monthly withdrawal bleed has no health benefit, and continuous or extended combined hormonal contraceptive regimens are considered as safe and effective for contraception as standard cyclic use.

Reference: FSRH Guideline: Combined Hormonal Contraception (January 2019, amended October 2023) — https://www.fsrh.org/Common/Uploaded%20files/documents/fsrh-guideline-combined-hormonal-contraception-october-2023.pdf